Skip to main content
Premium Trial:

Request an Annual Quote

PerkinElmer Acquires Indian Diagnostics Firm

NEW YORK (GenomeWeb) – PerkinElmer announced after the close of the market on Monday that it has acquired Tulip Diagnostics Private, a provider of in vitro diagnostic reagents, kits, and instruments to diagnostic labs, and government and private healthcare facilities in India.

The company expects the transaction to close in the first quarter of 2017. Further terms of the deal were not disclosed.

Privately held Tulip's products include tests for the prevention, screening, and diagnosis of infectious diseases such as malaria, HIV, and hepatitis, PerkinElmer said, adding that the deal expands its own position in emerging market diagnostics.

"We are committed to expanding our infectious disease screening menu and capabilities, and Tulip's product portfolio, channel access, and broad footprint provide the key enablers to help accelerate our growth in this important market," Prahlad Singh, senior vice president and president of diagnostics at PerkinElmer, said in a statement.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.